Medtronic wins FDA nod for next-gen Simplera CGM

Medtronic (NYSE: MDT)+ got another boost for its CGM portfolio, adding to the collaboration with Abbott announced today.

Our sibling site, Drug Delivery Business Newsreported today that the medtech giant received FDA approval for its Simplera continuous glucose monitor (CGM).

Simplera, the company’s first disposable, all-in-one CGM, comes in at half the size of previous Medtronic CGMs. Its discreet design simplifies the insertion and wear process and eliminates the need for overtape.

Sign up for Blog Updates